Director Robert Dickey IV resigns over disagreement with management on financial disclosures

Emmaus Life Sciences, Inc.

Robert Dickey IV resigned from Emmaus board and audit committee effective Aug 4, 2022, citing disagreement with management.
Management provided data showing improved monthly sales since Q4 2021/Q1 2022 and projections for growth and debt paydown.
Dickey disagreed with the timeliness and adequacy of the information provided by management.
The resignation letter is filed as Exhibit 99.1 to the 8-K.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Robert Dickey IV

Director

EMMA · Emmaus Life Sciences, Inc.

Effective: 2022-08-04
Filed: August 10, 2022, 7:59 PM ET

By letter dated August 4, 2022, Robert Dickey IV resigned as a director of Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) over a disagreement with management of the company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Robert Dickey IV resigned as Director at Emmaus Life Sciences, Inc..

Action: resigned
Role: Director

Exact text from the filing

By letter dated August 4, 2022, Robert Dickey IV resigned as a director of Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) over a disagreement with management of the company.

View on SEC.gov

Emmaus Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-046326

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.